A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

NCT07629960 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

265

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Non-Small Cell Lung Cancer
Colorectal Neoplasms
Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: BLU-924

Sponsor

Blueprint Medicines Corporation

Collaborators

[object Object]